Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
NCT03702036 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2020-04-13
Summary
Compassionate use access to molibresib/GSK525762 for eligible participant with NUT Midline Carcinoma; indication is a seriously debilitating or life-threatening disease.
Conditions
Interventions
- DRUG
-
molibresib
molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
NCT06376136 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
NCT04570839 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer
NCT05576389 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029 ·Status: RECRUITING ·Phase: PHASE1
-
Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe
NCT04109261 ·Status: COMPLETED
-
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
NCT01525589 ·Status: COMPLETED ·Phase: PHASE2
-
PhII ICb With/Without Erbitux in MBC Pts
NCT00248287 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
NCT03803761 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
NCT06764186 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
NCT06460961 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT06612814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
NCT03620643 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06609187 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
NCT06481553 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
NCT07086196 ·Status: COMPLETED
-
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
NCT03839823 ·Status: COMPLETED ·Phase: PHASE2
-
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China
NCT04526028 ·Status: UNKNOWN
-
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT05918133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
AT13387 in Adults With Refractory Solid Tumors
NCT01246102 ·Status: COMPLETED ·Phase: PHASE1
-
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
NCT06603987 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT06126276 ·Status: RECRUITING ·Phase: PHASE2
-
Extended Treatment in Metastatic Breast Cancer With Eribulin
NCT02769364 ·Status: COMPLETED
-
Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
NCT06914661 ·Status: ENROLLING_BY_INVITATION
-
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
NCT06313086 ·Status: RECRUITING ·Phase: PHASE3